Lung Cancer: Targets and Therapy
Volume 10, 2019 - Issue
Open access
146
Views
7
CrossRef citations to date
0
Altmetric
Review
Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
Stephanie M Barrows1 Market Access and Outcomes Strategy, RTI Health Solutions, Ann Arbor, MI, USA, [email protected]Correspondence[email protected]
, Kelly Wright1 Market Access and Outcomes Strategy, RTI Health Solutions, Ann Arbor, MI, USA, [email protected]
, Catherine Copley-Merriman1 Market Access and Outcomes Strategy, RTI Health Solutions, Ann Arbor, MI, USA, [email protected]
, James A Kaye2 Epidemiology and Clinical Research, RTI Health Solutions, Waltham, MA, USA
, Marc Chioda3 Medical Affairs, Pfizer, Inc., New York, NY, USA
, Robin Wiltshire4 Medical Affairs, Pfizer Limited, Walton Oaks, UK
, Knut Martin Torgersen5 Medical Affairs, Pfizer, Inc., Oslo, Norway
& Elizabeth T Masters6 Health Economics and Outcomes Research, Pfizer, Inc., New York, NY, USA
show all
Pages 11-20
|
Published online: 08 Feb 2019
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.